


**Product Name** : Sunvozertinib  
**Cat. No.** : PC-38101  
**CAS No.** : 2370013-49-1  
**Molecular Formula** : C<sub>29</sub>H<sub>35</sub>ClFN<sub>7</sub>O<sub>3</sub>  
**Molecular Weight** : 584.093  
**Target** : EGFR  
**Solubility** : 10 mM in DMSO



## Biological Activity

DZD9008 (Sunvozertinib) is an oral, potent, irreversible, wild type-selective **EGFR** inhibitor against EGFR or HER2 Exon20ins and other mutations (IC<sub>50</sub>=0.4-2.1 nM).

DZD9008 downregulates pEGFR with IC<sub>50</sub> ranging from 1 to 22 nM in a panel of tumor cell lines expressing EGFR L858R, Exon19del, L858R/T790M, various Exon20ins or uncommon mutations.

DZD9008 shows similar potency against pHER2 in tumor cells with HER2 Exon20ins mutation, with IC<sub>50</sub> of 7 nM.

DZD9008 is less potent in modulating pEGFR in tumor cells expressing wild type EGFR (IC<sub>50</sub>>80 nM).

DZD9008 suppressed cell proliferation with GI<sub>50</sub> of 1 to 60 nM in tumor cells carrying EGFR L858R, Exon19del, L858R/T790M, various Exon20ins or uncommon mutations in cell proliferation assays.

DZD9008 exhibits tumor growth inhibition and regression in CDX and PDX models carrying EGFR Exon19del single mutation, L858R/T790M double mutations, and PDX models harboring G719S/L861Q or Exon20ins.

## References

Yan Xu, et al. AACR Abstract 3081, Cancer Res (2019) 79 (13\_Supplement): 3081.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com